PHIO PHARMACEUTICALS CORP. Impairment of Long-Lived Assets Held-for-use
PHIO PHARMACEUTICALS CORP. (PHIO) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2025-03-31
- PHIO PHARMACEUTICALS CORP. impairment of long-lived assets held-for-use for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- PHIO PHARMACEUTICALS CORP. impairment of long-lived assets held-for-use for fiscal 2023 was $126.00K.
- PHIO PHARMACEUTICALS CORP. impairment of long-lived assets held-for-use for fiscal 2022 was $0.00.
- PHIO PHARMACEUTICALS CORP. impairment of long-lived assets held-for-use for fiscal 2021 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-31 |
| 2023-12-31 | $126.00K 10-K · filed 2025-03-31 |
| 2022-12-31 | $0.00 10-K · filed 2024-04-01 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-22 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-22 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-25 |
| 2018-12-31 | $0.00 10-K · filed 2019-03-27 |
| 2017-12-31 | $9.00K 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |